|
Putchner MJA, et al. 2010 [4]
|
1 Anaplstic
|
60Gy RT
|
10 mg/kg every 2 weeks
|
6 months
|
N/A
|
1 PR
|
N/A
|
hypertension
|
|
Goutagny S, et al. 2011 [17]
|
7 tumors in NF2 pts
|
none
|
5 mg/kg Every 2 weeks
|
15 months
|
volume
|
1 tumor: 22 % decrease
|
N/A
|
No mention
|
|
6 tumors N/C
|
|
Lou E, et al. 2012 [5]
|
5 GI
|
RT: 12/14
|
10 mg/kg very 2 weeks
|
0.5–29.5 months
|
RANO
|
0 CR
|
mPFS: 17.9 months
|
Tumoral hemorrhage
|
|
5 GII
|
CT: 11/14
| | | |
1 PR
|
PFS-6: 85.7 %
|
G4 intestinal perforation
|
|
3 GIII
| | | | |
11 SD
| |
G5 pneumonia/sepsis
|
|
1 unk
| | | | |
2 PD
| | |
|
Nayak L, et al. 2012 [18]
|
6 GII
|
RT: 15/15
|
10 mg/kg every 2 weeks
|
9 doses (1–19 doses)
|
RANO
|
0 CR
|
mPFS: 26 weeks
|
G1 Intratumoral hemorrhage
|
|
9 GIII
|
CT: 7/15
| | | |
0 PR
|
mOS: 15 months
|
G2 fatigue
|
| | | | | |
15 SD
| | |
|
Nunes FP, et al. 2013 [19]
|
48 tumors in 15 NF2 pts
| |
5 mg/kg every 2 weeks
| |
Response: 20 % reduction
|
Tumor: 29 % response
|
Per-tumor
|
4 G3 events
|
|
Progression: 20 % increase
|
Patients
|
PFS-6: 85 %
|
2 G4 events (wound healing problems)
|
| |
7 % response
|
Per-patient
| |
| | |
PFS-6: 93 %
| |
|
Boström JP, et al. 2014 [20]
|
1 GIII
|
60Gy RT
|
5 mg/kg every 2 weeks
|
2 months
|
N/A
|
Stable and growing
|
N/A
|
No mention
|
| |
35Gy SRT
| | | | | | |
